A5049071496- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- Health Systems, Economic Evaluations, Quality of Life
- Nerve Injury and Rehabilitation
- Shoulder Injury and Treatment
- Head and Neck Cancer Studies
- Biosimilars and Bioanalytical Methods
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Synthesis and Biological Evaluation
- Insect Resistance and Genetics
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Orthopedic Surgery and Rehabilitation
- Epigenetics and DNA Methylation
- Peripheral Nerve Disorders
- Cancer survivorship and care
- Colorectal and Anal Carcinomas
- Statistical Methods in Clinical Trials
- Lymphatic System and Diseases
- Bladder and Urothelial Cancer Treatments
- Menopause: Health Impacts and Treatments
- Meta-analysis and systematic reviews
Ramakrishna Mission Vivekananda Educational and Research Institute
2025
Johnson & Johnson (United Kingdom)
2024
Janssen (United Kingdom)
2020-2023
Erasmus MC Cancer Institute
2023
University of Warwick
2015-2022
MRC Human Nutrition Research
2013
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety efficacy of cilta-cel, an anti-BCMA chimeric receptor T therapy, in various patient populations. Patients cohort C progressed despite treatment with proteasome inhibitor, immunomodulatory drug, anti-CD38...
In this first-in-human, Phase 1, open-label, multicenter study, we evaluated JNJ-64619178, a selective and potent PRMT5 inhibitor, in patients with advanced malignant solid tumors or non-Hodgkin lymphomas (NHL). The primary objective was to evaluate the safety identify recommended 2 dose (RP2D) of JNJ-64619178.Adult treatment-refractory NHL measurable disease received escalating doses JNJ-64619178 following two schedules (Schedule A: 14 days on/7 off; Schedule B: every day on 21-day cycle)....
Abstract Objective To evaluate whether a structured exercise programme improved functional and health related quality of life outcomes compared with usual care for women at high risk upper limb disability after breast cancer surgery. Design Multicentre, pragmatic, superiority, randomised controlled trial economic evaluation. Setting 17 UK National Health Service centres. Participants 392 undergoing surgery, postoperative morbidity, (1:1) to (n=196) or alone (n=196). Interventions Usual...
Shea butter, derived from the nuts of African shea tree (Vitellaria paradoxa), is a versatile natural fat with numerous applications in food industry. Traditionally used West cuisine, butter serves as cooking oil, imparting mild, nutty flavour to dishes, while also being utilized for frying and sautéing. Its stable solid form at room temperature makes it an excellent ingredient margarine production, providing rich, creamy texture. butter's use cocoa substitute chocolate confectionery...
Background Upper limb problems are common after breast cancer treatment. Objectives To investigate the clinical effectiveness and cost-effectiveness of a structured exercise programme compared with usual care on upper function, health-related outcomes costs in women undergoing surgery. Design This was two-arm, pragmatic, randomised controlled trial embedded qualitative research, process evaluation parallel economic analysis; unit randomisation individual (allocated ratio 1 : 1). Setting...
8029 Background: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study, efficacy and safety cilta-cel are being evaluated in patients (pts) with MM who had early relapse after initial therapy. These pts have functionally high-risk disease, post autologous stem cell transplantation (ASCT) a poor prognostic factor representing an unmet medical need. We present updated results. Methods: Eligible MM, received 1 prior LOT (PI IMiD required), disease progression per IMWG (either...
7505 Background: CARTITUDE-2 is a phase 2 multicohort study evaluating ciltacabtagene autoleucel (cilta-cel) across various clinical settings. Cohort D cilta-cel ± lenalidomide (len) maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM) who achieved less than complete response (CR) after autologous stem cell transplant (ASCT) frontline therapy (tx). We report efficacy and safety for this cohort. Methods: Adults NDMM per IMWG criteria, best of <CR ≥stable disease 4–8...
Introduction: Menopausal problems are among the most prevalent and distressing following breast cancer treatment, with 70% women experiencing hot flushes night sweats (HFNS). A working party was set up to support development of new research into management these problems.Methods: We conducted surveys explore need as perceived by establish current UK practices. patient survey through a charity, Breast Cancer Care, health professional via Intergroup. The HFNS Problem Rating Scale used, well...
BackgroundThe De-ESCALaTE HPV trial confirmed the dominance of cisplatin over cetuximab for tumour control in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here, we present analysis health-related quality life (HRQoL), resource use, and health care costs trial, as well complete 2-year survival recurrence.Materials methodsResource use HRQoL data were collected at intervals from baseline to 24 months post treatment (PT). Health estimated using...
Background: Guidelines from the National Comprehensive Cancer Network recommend daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) as induction therapy followed by autologous stem cell transplant (ASCT), consolidation, maintenance for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). In phase 1b/2 CARTITUDE-1 study, a single infusion of ciltacabtagene autoleucel (cilta-cel), chimeric antigen receptor (CAR)-T two B-cell maturation (BCMA)-targeting...
An abstract is not available for this content. As you have access to content, full HTML content provided on page. A PDF of also in through the 'Save PDF' action button.
An abstract is not available for this content. As you have access to content, full HTML content provided on page. A PDF of also in through the 'Save PDF' action button.
8020 Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study is evaluating cilta-cel safety and efficacy in pts with MM who received 1–3 prior LOT were len-refractory – a difficult-to-treat population poor prognosis. We present updated results. Methods: Pts had progressive after LOT, including PI IMiD, len-refractory, no exposure to BCMA-targeting agents. single infusion (target dose 0.75×10 6 CAR+ viable T cells/kg) was given post lymphodepletion. Safety assessed,...
Abstract Background This study aims to develop and validate a new classification system that better predicts combined risk of neurological neurovascular complications following CBT surgery, crucial for treatment decision‐making. Methods Multinational retrospective cohort with 199 consecutive cases. A 132 cases was used the classification. To undertake external validation, assessment made between actual complication rate predicted by model on an independent ( n = 67). Results Univariate...